Stay updated on GT90001+Nivolumab in Metastatic HCC Clinical Trial
Sign up to get notified when there's something new on the GT90001+Nivolumab in Metastatic HCC Clinical Trial page.

Latest updates to the GT90001+Nivolumab in Metastatic HCC Clinical Trial page
- CheckyesterdayNo Change Detected
- Check9 days agoChange DetectedA new page revision tag 'Revision: v3.5.3' was added, replacing the previous revision tag. This indicates a version update for the page without altering the study details.SummaryDifference0.1%

- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check52 days agoChange DetectedAdded Hepatocellular carcinoma as a condition reference and linked the Genetic and Rare Diseases Information Center under Resources; updated the page revision from v3.4.3 to v3.5.0.SummaryDifference0.2%

- Check59 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check87 days agoChange DetectedThe page shows a new footer revision 'Revision: v3.4.2' and removes the government funding status notice (formerly 'Revision: v3.4.1'). This appears to be a routine site maintenance update with no effect on the study content or results.SummaryDifference0.4%

- Check94 days agoChange DetectedA global banner about government funding and NIH operations was added, with links to cc.nih.gov and opm.gov, and the site revision updated to v3.4.1.SummaryDifference0.4%

Stay in the know with updates to GT90001+Nivolumab in Metastatic HCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the GT90001+Nivolumab in Metastatic HCC Clinical Trial page.